PRLD (Prelude Therapeutics) 3-1 Month Momentum %: 2.75% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRLD Prelude Therapeutics Inc PRLD
22 GF Score
Price $4.47
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics 3-1 Month Momentum %?

Prelude Therapeutics PRLD +0.79% 22 3-1 Month Momentum % is 2.75% as of Jul. 14, 2026. GuruFocus rates PRLD with a GF Score™ of 22/100. The stock has 6 warning signs investors should review. Among 1,385 Biotechnology companies, Prelude Therapeutics ranks better than 72.49% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-14), Prelude Therapeutics's 3-1 Month Momentum % is 2.75%.

The industry rank for Prelude Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

PRLD's 3-1 Month Momentum % is ranked better than
72.49% of 1385 companies
in the Biotechnology industry
Industry Median: -10.59 vs PRLD: 2.75

Prelude Therapeutics  (NAS:PRLD) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Prelude Therapeutics 3-1 Month Momentum % Related Terms

PRLD vs DMAC, RCKT, CYDY: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Prelude Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prelude Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Prelude Therapeutics's 3-1 Month Momentum % falls into.


PRLD
22GF Score
Prelude Therapeutics Inc PRLD
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics  (NAS:PRLD) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 2.75% mean?
Prelude Therapeutics (PRLD) has a 3-1 Month Momentum % of 2.75% as of Jul. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Prelude Therapeutics and its competitors. According to the industry distribution chart, Prelude Therapeutics ranks #381 out of 1385 companies in the Biotechnology industry, placing it in the top 27.5%.
Is Prelude Therapeutics' 3-1 Month Momentum % too high?
Prelude Therapeutics' current 3-1 Month Momentum % is 2.75%. Based on the distribution chart, Prelude Therapeutics ranks #381 out of 1385 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' 3-1 Month Momentum % compare to DMAC and RCKT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #381 out of 1385 companies for 3-1 Month Momentum %. This puts Prelude Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Prelude Therapeutics and its competitors. Prelude Therapeutics's current 3-1 Month Momentum % is 2.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current 3-1 Month Momentum % of 2.75%. The current 3-1 Month Momentum % is 2.75%. Prelude Therapeutics' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current 3-1 Month Momentum % is 2.75% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
22GF Score

Get the complete analysis for PRLD

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.47
Price